An automated microscale chromatographic purification of virus-like particles as a strategy for process development.
The development of fermentation processes for recombinant vaccines requires optimizing expression while maintaining high product quality. Changes to cell fermentation conditions are typically evaluated following cell disruption, with expression levels quantified by immunoassay, liquid chromatography or enzyme activity. However, assay titres do not always predict the effects that intracellular aggregation, proteolysis, post-translational modifications and differences in relative impurity levels can have on purification yield and product purity. Furthermore, heterogeneity in the size and surface properties inherent in viral particles makes unit operations such as chromatography less predictable. In these cases, the purification procedure (or a mimic thereof) must be carried out to give accurate information on the impact of changes in fermentation conditions on purification process performance. This was demonstrated for the development of a recombinant vaccine against human papillomavirus produced in Saccharomyces cerevisiae, where the most informative feedback on fermentation variables was obtained by completing a multistep chromatographic purification to evaluate process yield and product purity. To increase the purification throughput and reduce labour, the chromatography was miniaturized 1000-fold from the laboratory scale using microlitre volumes of adsorbent in a pipette tip and automated on a robotic workstation. The microscale purification is shown to be predictive of the laboratory-scale purification in terms of yield and purity, while providing over a 10-fold increase in throughput and allowing for increased monitoring of fermentation processes. In addition, by reducing the volume of cells needed for this assessment, the fermentation can be correspondingly reduced in scale and carried out in parallel for additional throughput gains.
Wenger
Marc D
MD
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London, UK. marc_wenger@merck.com
Dephillips
Peter
P
Price
Colleen E
CE
Bracewell
Daniel G
DG
D002853:Chromatography, Liquid / Q000379:methods*; D044085:Microfluidics / Q000379:methods*; D008904:Miniaturization; D027383:Papillomaviridae / Q000235:genetics / Q000378:metabolism*; D053918:Papillomavirus Vaccines / Q000302:isolation & purification; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000627:therapeutic use; D012441:Saccharomyces cerevisiae / Q000821:virology*; D014771:Virion / Q000302:isolation & purification* / Q000378:metabolism*; D014776:Virus Cultivation / Q000379:methods*
D053918:Papillomavirus Vaccines; D011994:Recombinant Proteins